RayzeBio Snags $45M to Reimagine Targeted Radiotherapies for Cancer

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Reviving Targeted Radiopharmaceuticals for Cancer: Ken Song on The Long Run
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M